Outcomes of First-Line Chemotherapy in Patients with Advanced or Metastatic Leiomyosarcoma of Uterine and Non-Uterine Origin

Table 2

Treatment characteristics.

	Non-Uterine	%	Uterine	%
	(𝑛=32)		(𝑛=33)
Chemotherapy
Yes	32		33
Induction chemotherapy (for locally advanced disease)	5		4
No	27		29
Chemotherapeutic regimen
Monotherapy
Doxorubicine 75 mg/m^2, q 3 wk	17	53	20	61
Ifosfamide 9 gr/m^2, q 3 wk	8	25	7	21
Ifosfamide 5 gr/m^2 in 24 hrs, q 3 wk	1		0
Epirubicine 150 mg/m^2, q 3 wk	1		1
Docetaxel 100 mg/m^2, q 3 wk	1		1
Combination
Doxorubicine 75 mg/m^2+ ifosfamide 9 gr/m^2, q 3 wk	0		1
Doxorubicine 75 mg/m^2+ ifosfamide 10 gr/m^2 (4 × 2.5), q 3 wk	2		1
Doxorubicine 75 mg/m^2+ ifosfamide 5 gr/m^2, q 3 wk	0		1
Doxorubicine 50 mg/m^2+ ifosfamide 5 gr/m^2 dg 1, q 3 wk	1		1
Doxorubicine 60 mg/m^2+ ifosfamide 5 gr/m^2, q 3 wk	1		0
Median number of cycles	4	(1–7)	4	(1–7)